Meticulous Research® Predicts Vaccines Market to Reach $71.50 Billion by 2031
” |
Meticulous
Research® has released its latest report forecasting that the global vaccines
market will reach $71.50 billion by 2031, growing at a compound annual
growth rate (CAGR) of 2.3% over the forecast period. Key drivers of this
market growth include a robust pipeline for vaccines, increased government
immunization initiatives, and significant technological advancements in
vaccine development. Additionally, the rising prevalence of various diseases,
a growing focus on therapeutic vaccines, and promising growth in emerging
markets present substantial opportunities for market players.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5076
However, the market faces challenges such
as the high costs associated with vaccine development and lengthy
manufacturing timelines. Product recalls and limited access to vaccines
further constrain market growth.
1.1.1 Leading Market Players
Prominent companies in the vaccines
market include:
- Sanofi (France)
- Merck & Co., Inc.
(U.S.)
- GlaxoSmithKline plc
(U.K.)
- Pfizer Inc. (U.S.)
- Johnson & Johnson
(U.S.)
- Daiichi Sankyo Co., Ltd.
(Japan)
- Takeda Pharmaceutical
Company Limited (Japan)
- CSL Limited (Australia)
- Emergent BioSolutions
Inc. (U.S.)
- AstraZeneca PLC (U.K.)
1.1.2 Market Segmentation and Future Outlook
1.1.2.1 By
Indication
The vaccines market is segmented by
indication into:
- Pneumococcal
Disease
- Influenza
- Human
Papillomavirus (HPV)
- Diphtheria,
Tetanus, and Pertussis (DTP)
- Meningococcal
Disease
- Measles,
Mumps, and Rubella (MMR)
- Rotavirus
- Poliomyelitis
(Polio)
- Hepatitis
- COVID-19
- Other
Indications
Request Sample Report Here @ https://www.meticulousresearch.com/request-sample-report/cp_id=5076
In 2024, the pneumococcal disease segment is anticipated to
hold the largest market share, driven by the rising incidence of diseases such
as pneumonia, meningitis, febrile bacteremia, otitis media, and sinusitis, as
well as the development of high-quality vaccines like PPSV23.
1.1.2.2 By Route of
Administration
The market is categorized by route of
administration into:
- Intramuscular
(IM)
- Subcutaneous
(SC)
- Oral
- Other
Routes
The intramuscular (IM) segment is
expected to dominate in 2024, attributed to the ease of administration and
rapid absorption associated with this method. The COVID-19 pandemic has
further bolstered the adoption of the intramuscular route, with many COVID-19
vaccines being administered this way.
1.1.2.3 By Type
The vaccines market is classified by type
into:
- Subunit
& Conjugate Vaccines
- Inactivated
Vaccines
- Live-Attenuated
Vaccines
- Toxoid
Vaccines
- Combination
Vaccines
In 2024, the subunit & conjugate
vaccines segment is projected to lead, thanks to their long-term immunity,
high safety, and stability compared to other vaccine types.
1.1.2.4 By Valence
The market is divided by valence into:
- Multivalent
Vaccines
- Monovalent
Vaccines
The multivalent vaccines segment is
expected to hold a larger share in 2024, due to the launch of new multivalent
vaccines, increased R&D investments, and technological advancements in
their production.
1.1.3 Geographic Analysis
This comprehensive report provides an
in-depth analysis of key regions including:
- North America (U.S. and Canada)
- Europe (Germany, France,
U.K., Italy, Spain, Switzerland, Netherlands, and Rest of Europe)
- Asia-Pacific (China, Japan,
India, Australia, South Korea, and Rest of Asia-Pacific)
- Latin America (Brazil, Mexico,
Rest of Latin America)
- Middle East & Africa
North America is projected to command the
largest share of the vaccines market in 2024, with a 41.2% share, followed by
Europe and Asia-Pacific. The significant market presence in North America is
attributed to active research & development, frequent product launches,
and the establishment of new facilities by key industry players.
Quick Buy @ https://www.meticulousresearch.com/Checkout/94492906
1.1.4 Conclusion
The vaccines market is poised for steady
growth, driven by innovative advancements and increasing global health
initiatives. Despite challenges, the market offers significant opportunities,
particularly in emerging regions and through the development of new vaccine
technologies. Meticulous Research® will continue to monitor and analyze these
trends, providing valuable insights to industry stakeholders.
About
Meticulous Research®
Meticulous Research® was founded in 2010
and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private
limited company under the Companies Act, 1956. Since its incorporation, the
company has become the leading provider of premium market intelligence in
North America, Europe, Asia-Pacific, Latin America, and the Middle East &
Africa.
The name of our company defines our
services, strengths, and values. Since the inception, we have only thrived to
research, analyze, and present the critical market data with great attention
to details. With the meticulous primary and secondary research techniques, we
have built strong capabilities in data collection, interpretation, and
analysis of data including qualitative and quantitative research with the
finest team of analysts. We design our meticulously analyzed intelligent and
value-driven syndicate market research reports, custom studies, quick
turnaround research, and consulting solutions to address business challenges
of sustainable growth.
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment